The dopaminergic system in autoimmune diseases

Frontiers in Immunology

Volumn 5, Issue MAR, 2014, Pages

  Pacheco, Rodrigo ^a,b   Contreras, Francisco ^a,c   Zouali, Moncef ^d,e  

^a Fundacion Ciencia para la Vida   (Chile)

^b UNIVERSIDAD SAN SEBASTIÁN   (Chile)

^c UNIVERSIDAD ANDRÉS BELLO   (Chile)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Crohn's disease; Dendritic cell; Multiple sclerosis; Regulatory T cell; Rheumatoid arthritis; Systemic lupus erythematosus; Th 17; Ulcerative colitis

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; SUPEROXIDE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; VESICULAR MONOAMINE TRANSPORTER;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DIFFERENTIATION; DENDRITIC CELL; DOPAMINERGIC SYSTEM; ENZYME REGULATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM FUNCTION; NERVOUS SYSTEM INFLAMMATION; PATHOGENESIS; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; ULCERATIVE COLITIS;

EID: 84897944703     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00117     Document Type: Review

References (126)

1. Blalock JE. The syntax of immune-neuroendocrine communication. Immunol Today (1994) 15:504-11. doi:10.1016/0167-5699(94)90205-4
2. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S. The immunoregulatory role of dopamine: an update. Brain Behav Immun (2010) 24:525-8. doi:10.1016/j.bbi.2009.10.015
3. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D, et al. Dopamine receptor expression on human T-and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol (2002) 132:34-40. doi:10.1016/S0165-5728(02)00280-1
4. Pacheco R, Prado CE, Barrientos MJ, Bernales S. Role of dopamine in the physiology of T-cells and dendritic cells. J Neuroimmunol (2009) 216:8-19. doi:10.1016/j.jneuroim.2009.07.018
5. Pacheco R, Riquelme E, Kalergis AM. Emerging evidence for the role of neurotransmitters in the modulation of T cell responses to cognate ligands. Cent Nerv Syst Agents Med Chem (2010) 10:65-83. doi:10.2174/187152410790780154
6. Prado C, Bernales S, Pacheco R. Modulation of T-cell mediated immunity by dopamine receptor D5. Endocr Metab Immune Disord Drug Targets (2013) 13:184-94. doi:10.2174/1871530311313020007
7. Scheuermann DW. Comparative morphology, cytochemistry and innervation of chromaffin tissue in vertebrates. J Anat (1993) 183(Pt 2):327-42.
8. Eisenhofer G, Aneman A, Friberg P, Hooper D, Fåndriks L, Lonroth H, et al. Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab (1997) 82:3864-71. doi:10.1210/jc.82.11.3864
9. Vieira-Coelho MA, Soares-da-Silva P. Dopamine formation, from its immediate precursor 3,4-dihydroxyphenylalanine, along the rat digestive tract. Fundam Clin Pharmacol (1993) 7:235-43. doi:10.1111/j.1472-8206.1993.tb00237.x
10. Shechter R, London A, Schwartz M. Orchestrated leukocyte recruitment to immune-privileged sites: absolute barriers versus educational gates. Nat Rev Immunol (2013) 13:206-18. doi:10.1038/nri3391
11. Hatterer E, Touret M, Belin MF, Honnorat J, Nataf S. Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions. PLoS One (2008) 3:e3321. doi:10.1371/journal.pone.0003321
12. Laman JD, Weller RO. Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J Neuroimmune Pharmacol (2013) 8:840-56. doi:10.1007/s11481-013-9470-8
13. Anandasabapathy N, Victora GD, Meredith M, Feder R, Dong B, Kluger C, et al. Flt3L controls the development of radiosensitive dendritic cells in the meninges and choroid plexus of the steady-state mouse brain. J Exp Med (2011) 208:1695-705. doi:10.1084/jem.20102657
14. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun (2011) 25:181-213. doi:10.1016/j.bbi.2010.10.015
15. Derecki NC, Cardani AN, Yang CH, Quinnies KM, Crihfield A, Lynch KR, et al. Regulation of learning and memory by meningeal immunity: a key role for IL-4. J Exp Med (2010) 207:1067-80. doi:10.1084/jem.20091419
16. Radjavi A, Smirnov I, Kipnis J. Brain antigen-reactive CD4 T cells are sufficient to support learning behavior in mice with limited T cell repertoire. Brain Behav Immun (2013) 35:58-63. doi:10.1016/j.bbi.2013.08.013
17. Baruch K, Schwartz M. CNS-specific T cells shape brain function via the choroid plexus. Brain Behav Immun (2013) 34:11-6. doi:10.1016/j.bbi.2013.04.002
18. Lewitus GM, Schwartz M. Behavioral immunization: immunity to self-antigens contributes to psychological stress resilience. Mol Psychiatry (2009) 14:532-6. doi:10.1038/mp.2008.103
19. Lucin KM, Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little? Neuron (2009) 64:110-22. doi:10.1016/j.neuron.2009.08.039
20. Appel SH. CD4+ T cells mediate cytotoxicity in neurodegenerative diseases. J Clin Invest (2009) 119:13-5. doi:10.1172/JCI38096
21. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest (2009) 119:182-92. doi:10.1172/JCI36470
22. González H, Contreras F, Prado C, Elgueta D, Franz D, Bernales S, et al. Dopamine receptor D3 expressed on CD4+ T cells favors neurodegeneration of dopaminergic neurons during Parkinson's disease. J Immunol (2013) 190:5048-56. doi:10.4049/jimmunol.1203121
23. Reynolds AD, Stone DK, Hutter JA, Benner EJ, Mosley RL, Gendelman HE. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol (2010) 184:2261-71. doi:10.4049/jimmunol.0901852
24. Barcia C, Ros CM, Annese V, Gómez A, Ros-Bernal F, Aguado-Llera D, et al. IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease. Cell Death Dis (2012) 3:e379. doi:10.1038/cddis.2012.123
25. Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, et al. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol Med (2013) 5:64-79. doi:10.1002/emmm.201201544
26. Mignini F, Tomassoni D, Traini E, Amenta F. Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen. J Neuroimmunol (2009) 206:5-13. doi:10.1016/j.jneuroim.2008.09.018
27. Härle P, Pongratz G, Albrecht J, Tarner IH, Straub RH. An early sympathetic nervous system influence exacerbates collagen-induced arthritis via CD4+CD25+ cells. Arthritis Rheum (2008) 58:2347-55. doi:10.1002/art.23628
28. Bhowmick S, Singh A, Flavell RA, Clark RB, O'Rourke J, Cone RE. The sympathetic nervous system modulates CD4(+)FoxP3(+) regulatory T cells via a TGF-beta-dependent mechanism. J Leukoc Biol (2009) 86:1275-83. doi:10.1189/jlb.0209107
29. Grebe KM, Hickman HD, Irvine KR, Takeda K, Bennink JR, Yewdell JW. Sympathetic nervous system control of anti-influenza CD8+ T cell responses. Proc Natl Acad Sci U S A (2009) 106:5300-5. doi:10.1073/pnas.0808851106
30. Miura T, Kudo T, Matsuki A, Sekikawa K, Tagawa Y, Iwakura Y, et al. Effect of 6-hydroxydopamine on host resistance against Listeria monocytogenes infection. Infect Immun (2001) 69:7234-41. doi:10.1128/IAI.69.12.7234-7241.2001
31. Alaniz RC, Thomas SA, Perez-Melgosa M, Mueller K, Farr AG, Palmiter RD, et al. Dopamine beta-hydroxylase deficiency impairs cellular immunity. Proc Natl Acad Sci U S A (1999) 96:2274-8. doi:10.1073/pnas.96.5.2274
32. Franco R, Pacheco R, Lluis C, Ahern GP, O'Connell PJ. The emergence of neurotransmitters as immune modulators. Trends Immunol (2007) 28:400-7. doi:10.1016/j.it.2007.07.005
33. Cosentino M, Marino F, Bombelli R, Ferrari M, Rasini E, Lecchini S, et al. Stimulation with phytohaemagglutinin induces the synthesis of catecholamines in human peripheral blood mononuclear cells: role of protein kinase C and contribution of intracellular calcium. J Neuroimmunol (2002) 125:125-33. doi:10.1016/S0165-5728(02)00019-X
34. Ferrari M, Cosentino M, Marino F, Bombelli R, Rasini E, Lecchini S, et al. Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes. Biochem Pharmacol (2004) 67:865-73. doi:10.1016/j.bcp.2003.10.004
35. Prado C, Contreras F, González H, Díaz P, Elgueta D, Barrientos M, et al. Stimulation of dopamine receptor D5 expressed on dendritic cells potentiates Th17-mediated immunity. J Immunol (2012) 188:3062-70. doi:10.4049/jimmunol.1103096
36. Nakano K, Higashi T, Takagi R, Hashimoto K, Tanaka Y, Matsushita S. Dopamine released by dendritic cells polarizes Th2 differentiation. Int Immunol (2009) 21:645-54. doi:10.1093/intimm/dxp033
37. Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, et al. Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood (2007) 109:632-42. doi:10.1182/blood-2006-01-028423
38. Cosentino M, Zaffaroni M, Ferrari M, Marino F, Bombelli R, Rasini E, et al. Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: implications for multiple sclerosis. J Neuroimmunol (2005) 162:112-21. doi:10.1016/j.jneuroim.2005.01.019
39. Beck GC, Brinkkoetter P, Hanusch C, Schulte J, van Ackern K, van derWoude FJ, et al. Clinical review: immunomodulatory effects of dopamine in general inflammation. Crit Care (2004) 8:485-91. doi:10.1186/cc2879
40. Cosentino M, Bombelli R, Ferrari M, Marino F, Rasini E, Maestroni GJ, et al. HPLC-ED measurement of endogenous catecholamines in human immune cells and hematopoietic cell lines. Life Sci (2000) 68:283-95. doi:10.1016/S0024-3205(00)00937-1
41. Yong LC. The mast cell: origin, morphology, distribution, and function. Exp Toxicol Pathol (1997) 49:409-24. doi:10.1016/S0940-2993(97)80129-7
42. Besser MJ, Ganor Y, Levite M. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both. J Neuroimmunol (2005) 169:161-71. doi:10.1016/j.jneuroim.2005.07.013
43. Saha B, Mondal AC, Majumder J, Basu S, Dasgupta PS. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation (2001) 9:23-33. doi:10.1159/000049004
44. Sarkar C, Das S, Chakroborty D, Chowdhury UR, Basu B, Dasgupta PS, et al. Cutting Edge: Stimulation of dopamine D4 receptors induce T cell quiescence by up-regulating Kruppel-like factor-2 expression through inhibition of ERK1/ERK2 phosphorylation. J Immunol (2006) 177:7525-9.
45. Watanabe Y, Nakayama T, Nagakubo D, Hieshima K, Jin Z, Katou F, et al. Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3. J Immunol (2006) 176:848-56.
46. Kipnis J, Cardon M, Avidan H, Lewitus GM, Mordechay S, Rolls A, et al. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. J Neurosci (2004) 24:6133-43. doi:10.1523/JNEUROSCI.0600-04.2004
47. Ilani T, Strous RD, Fuchs S. Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells. FASEB J (2004) 18:1600-2. doi:10.1096/fj.04-1652fje
48. Saha B, Mondal AC, Basu S, Dasgupta PS. Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4+ and CD8+ T cells by D1 dopamine receptors: an in vitro analysis. Int Immunopharmacol (2001) 1:1363-74. doi:10.1016/S1567-5769(01)00068-6
49. Sunahara RK, Guan HC, O'Dowd BF, Seeman P, Laurier LG, Ng G, et al. Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature (1991) 350:614-9. doi:10.1038/350614a0
50. Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature (1991) 350:610-4. doi:10.1038/350610a0
51. Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature (1990) 347:146-51. doi:10.1038/347146a0
52. Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S. Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun (2008) 373:286-91. doi:10.1016/j.bbrc.2008.06.012
53. Chastain EM, Duncan DS, Rodgers JM, Miller SD. The role of antigen presenting cells in multiple sclerosis. Biochim Biophys Acta (2011) 1812:265-74. doi:10.1016/j.bbadis.2010.07.008
54. Jadidi-Niaragh F, Mirshafiey A. Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis. Neuropharmacology (2010) 59:180-9. doi:10.1016/j.neuropharm.2010.05.005
55. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T, et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med (2005) 11:328-34. doi:10.1038/nm1197
56. Tsai PJ, Huang PC. Circadian variations in plasma and erythrocyte concentrations of glutamate, glutamine, and alanine in men on a diet without and with added monosodium glutamate. Metabolism (1999) 48:1455-60. doi:10.1016/S0026-0495(99)90159-2
57. Bailey SL, Schreiner B, McMahon EJ, Miller SD. CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. Nat Immunol (2007) 8:172-80. doi:10.1038/ni1430
58. Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol (2010) 162:1-11. doi:10.1111/j.1365-2249.2010.04143.x
59. Barr TA, Shen P, Brown S, Lampropoulou V, Roch T, Lawrie S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med (2012) 209:1001-10. doi:10.1084/jem.20111675
60. Evdoshenko E, Maslyanskiy A, Lapin S, Zaslavsky L, Dobson R, Totolian A, et al. Dynamics of B-cell populations in CSF and blood in patients treated with a combination of rituximab and mitoxantrone. ISRN Neurol (2013) 2013:748127. doi:10.1155/2013/748127
61. Balkowiec-Iskra E, Kurkowska-Jastrzebska I, Joniec I, Ciesielska A, Czlonkowska A, Czlonkowski A. Dopamine, serotonin and noradrenaline changes in the striatum of C57BL mice following myelin oligodendrocyte glycoprotein (MOG) 35-55 and complete Freund adjuvant (CFA) administration. Acta Neurobiol Exp (Wars) (2007) 67:379-88.
62. Giorelli M, Livrea P, Trojano M. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta. J Interferon Cytokine Res (2005) 25:395-406. doi:10.1089/jir.2005.25.395
63. Zaffaroni M, Marino F, Bombelli R, Rasini E, Monti M, Ferrari M, et al. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Exp Neurol (2008) 214:315-21. doi:10.1016/j.expneurol.2008.08.015
64. Petermann F, Rothhammer V, Claussen MC, Haas JD, Blanco LR, Heink S, et al. gammadelta T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism. Immunity (2010) 33:351-63. doi:10.1016/j.immuni.2010.08.013
65. Codarri L, Gyülvészi G, Tosevski V, Hesske L, Fontana A, Magnenat L, et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol (2011) 12:560-7. doi:10.1038/ni.2027
66. Cosentino M, Zaffaroni M, Trojano M, Giorelli M, Pica C, Rasini E, et al. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-beta therapy. Neuroimmunomodulation (2012) 19:283-92. doi:10.1159/000336981
67. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol (2006) 12:6102-8. doi:10.3748/wjg.v12.i38.6102
68. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology (2012) 142:46.e-54.e. doi:10.1053/j.gastro.2011.10.001 quiz e30
69. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 369:1641-57. doi:10.1016/S0140-6736(07)60751-X
70. Brand S. Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease. Gut (2009) 58:1152-67. doi:10.1136/gut.2008.163667
71. Granlund Av, Flatberg A, Østvik AE, Drozdov I, Gustafsson BI, Kidd M, et al. Whole genome gene expression meta-analysis of inflammatory bowel disease colon mucosa demonstrates lack of major differences between Crohn's disease and ulcerative colitis. PLoS One (2013) 8:e56818. doi:10.1371/journal.pone.0056818
72. Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine (2011) 56:633-40. doi:10.1016/j.cyto.2011.08.036
73. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol (2010) 28:573-621. doi:10.1146/annurev-immunol-030409-101225
74. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol (2009) 9:313-23. doi:10.1038/nri2515
75. Kaser A, Blumberg RS. Endoplasmic reticulum stress in the intestinal epithelium and inflammatory bowel disease. Semin Immunol (2009) 21:156-63. doi:10.1016/j.smim.2009.01.001
76. Kamada N, Hisamatsu T, Okamoto S, Sato T, Matsuoka K, Arai K, et al. Abnormally differentiated subsets of intestinal macrophage play a key role in Th1-dominant chronic colitis through excess production of IL-12 and IL-23 in response to bacteria. J Immunol (2005) 175:6900-8.
77. Abe K, Nguyen KP, Fine SD, Mo JH, Shen C, Shenouda S, et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc Natl Acad Sci U S A (2007) 104:17022-7. doi:10.1073/pnas.0708469104
78. Fort MM, Leach MW, Rennick DM. A role for NK cells as regulators of CD4+ T cells in a transfer model of colitis. J Immunol (1998) 161:3256-61.
79. Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut (2003) 52:65-70. doi:10.1136/gut.52.1.65
80. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. J Exp Med (2007) 204:1849-61. doi:10.1084/jem.20070663
81. Powrie F, Mason D. OX-22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention by the OX-22low subset. J Exp Med (1990) 172:1701-8. doi:10.1084/jem.172.6.1701
82. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity (2008) 28:546-58. doi:10.1016/j.immuni.2008.02.017
83. Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, et al. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology (2005) 128:1868-78. doi:10.1053/j.gastro.2005.03.043
84. Saruta M, Yu QT, Fleshner PR, Mantel PY, Schmidt-Weber CB, Banham AH, et al. Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol (2007) 125:281-90. doi:10.1016/j.clim.2007.08.003
85. Monteleone G, Boirivant M, Pallone F, MacDonald TT. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol (2008) 1(Suppl 1):S50-3. doi:10.1038/mi.2008.55
86. Allez M, Brimnes J, Dotan I, Mayer L. Expansion of CD8+ T cells with regulatory function after interaction with intestinal epithelial cells. Gastroenterology (2002) 123:1516-26. doi:10.1053/gast.2002.36588
87. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol (2006) 176:705-10.
88. Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest (2004) 113:1490-7. doi:10.1172/JCI19836
89. Benarroch EE. Enteric nervous system: functional organization and neurologic implications. Neurology (2007) 69:1953-7. doi:10.1212/01.wnl.0000281999.56102.b5
90. Eaker EY, Bixler GB, Dunn AJ, Moreshead WV, Mathias JR. Dopamine and norepinephrine in the gastrointestinal tract of mice and the effects of neurotoxins. J Pharmacol Exp Ther (1988) 244:438-42.
91. Shichijo K, Sakurai-Yamashita Y, Sekine I, Taniyama K. Neuronal release of endogenous dopamine from corpus of guinea pig stomach. Am J Physiol (1997) 273:G1044-50.
92. Mitsuma T, Rhue H, Hirooka Y, Kayama M, Wago T, Takagi J, et al. Distribution of dopamine transporter in the rat: an immunohistochemical study. Endocr Regul (1998) 32:71-5.
93. Singaram C, Ashraf W, Gaumnitz EA, Torbey C, Sengupta A, Pfeiffer R, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet (1995) 346:861-4. doi:10.1016/S0140-6736(95)92707-7
94. Li ZS, Pham TD, Tamir H, Chen JJ, Gershon MD. Enteric dopaminergic neurons: definition, developmental lineage, and effects of extrinsic denervation. J Neurosci (2004) 24:1330-9. doi:10.1523/JNEUROSCI.3982-03.2004
95. Magro F, Vieira-Coelho MA, Fraga S, Serrão MP, Veloso FT, Ribeiro T, et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci (2002) 47:216-24. doi:10.1023/A:1013256629600
96. Magro F, Fraga S, Ribeiro T, Soares-da-Silva P. Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gamma upon L-DOPA uptake. Acta Physiol Scand (2004) 180:379-86. doi:10.1111/j.1365-201X.2004.01260.x
97. Straub RH, Grum F, Strauch U, Capellino S, Bataille F, Bleich A, et al. Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation. Gut (2008) 57:911-21. doi:10.1136/gut.2007.125401
98. Rosas-Ballina M, Olofsson PS, Ochani M, Valdés-Ferrer SI, Levine YA, Reardon C, et al. Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. Science (2011) 334:98-101. doi:10.1126/science.1209985
99. Matteoli G, Boeckxstaens GE. The vagal innervation of the gut and immune homeostasis. Gut (2013) 62:1214-22. doi:10.1136/gutjnl-2012-302550
100. Hernandez DE, Adcock JW, Orlando RC, Patrick KS, Nemeroff CB, Prange AJ Jr. Prevention of stress-induced gastric ulcers by dopamine agonists in the rat. Life Sci (1984) 35:2453-8. doi:10.1016/0024-3205(84)90454-5
101. Sikiric P, Geber J, Suchanek E, Ivanovic D, Gjuris V, Aleksic J, et al. The role of dopamine in the formation of gastric ulcers in rats. Eur J Pharmacol (1985) 112:127-8. doi:10.1016/0014-2999(85)90249-3
102. Miyazawa T, Matsumoto M, Kato S, Takeuchi K. Dopamine-induced protection against indomethacin-evoked intestinal lesions in rats-role of anti-intestinal motility mediated by D2 receptors. Med Sci Monit (2003) 9:BR71-7.
103. Magro F, Cunha E, Araujo F, Meireles E, Pereira P, Dinis-Ribeiro M, et al. Dopamine D2 receptor polymorphisms in inflammatory bowel disease and the refractory response to treatment. Dig Dis Sci (2006) 51:2039-44. doi:10.1007/s10620-006-9168-3
104. Zhang X, Guo H, Xu J, Li Y, Li L, Zhang X, et al. Dopamine receptor D1 mediates the inhibition of dopamine on the distal colonic motility. Transl Res (2012) 159:407-14. doi:10.1016/j.trsl.2012.01.002
105. Feng XY, Li Y, Li LS, Li XF, Zheng LF, Zhang XL, et al. Dopamine D1 receptors mediate dopamine-induced duodenal epithelial ion transport in rats. Transl Res (2013) 161:486-94. doi:10.1016/j.trsl.2012.12.002
106. Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A (2000) 97:8104-9. doi:10.1073/pnas.97.14.8104
107. Nakano K, Yamaoka K, Hanami K, Saito K, Sasaguri Y, Yanagihara N, et al. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol (2011) 186:3745-52. doi:10.4049/jimmunol.1002475
108. Nakashioya H, Nakano K, Watanabe N, Miyasaka N, Matsushita S, Kohsaka H. Therapeutic effect of D1-like dopamine receptor antagonist on collagen-induced arthritis of mice. Mod Rheumatol (2011) 21:260-6. doi:10.1007/s10165-010-0387-2
109. Klatt S, Fassold A, Straub RH. Sympathetic nerve fiber repulsion: testing norepinephrine, dopamine, and 17beta-estradiol in a primary murine sympathetic neurite outgrowth assay. Ann N Y Acad Sci (2012) 1261:26-33. doi:10.1111/j.1749-6632.2012.06628.x
110. Capellino S, Cosentino M, Wolff C, Schmidt M, Grifka J, Straub RH. Catecholamine-producing cells in the synovial tissue during arthritis: modulation of sympathetic neurotransmitters as new therapeutic target. Ann Rheum Dis (2010) 69:1853-60. doi:10.1136/ard.2009.119701
111. Jenei-Lanzl Z, Capellino S, Kees F, Fleck M, Lowin T, Straub RH. Anti-inflammatory effects of cell-based therapy with tyrosine hydroxylase-positive catecholaminergic cells in experimental arthritis. Ann Rheum Dis (2013). doi:10.1136/annrheumdis-2013-203925
112. McMurray RW. Bromocriptine in rheumatic and autoimmune diseases. Semin Arthritis Rheum (2001) 31:21-32. doi:10.1053/sarh.2001.25482
113. Mobini M, Kashi Z, Mohammad Pour AR, Adibi E. The effect of cabergoline on clinical and laboratory findings in active rheumatoid arthritis. Iran Red Crescent Med J (2011) 13:749-50. doi:10.5812/kowsar.20741804.2607
114. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med (2008) 358:929-39. doi:10.1056/NEJMra071297
115. Zouali M. Epigenetics in lupus. Ann N Y Acad Sci (2011) 1217:154-65. doi:10.1111/j.1749-6632.2010.05831.x
116. Karpuzoglu E, Zouali M. The multi-faceted influences of estrogen on lymphocytes: toward novel immuno-interventions strategies for autoimmunity management. Clin Rev Allergy Immunol (2011) 40:16-26. doi:10.1007/s12016-009-8188-0
117. Muscal E, Brey RL. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol Clin (2010) 28:61-73. doi:10.1016/j.ncl.2009.09.004
118. Diamond B, Volpe BT. A model for lupus brain disease. Immunol Rev (2012) 248:56-67. doi:10.1111/j.1600-065X.2012.01137.x
119. Kunas RC, McRae A, Kesselring J, Villiger PM. Antidopaminergic antibodies in a patient with a complex autoimmune disorder and rapidly progressing Parkinson's disease. J Allergy Clin Immunol (1995) 96:688-90. doi:10.1016/S0091-6749(95)70268-7
120. Anderson KK, Ballok DA, Prasad N, Szechtman H, Sakic B. Impaired response to amphetamine and neuronal degeneration in the nucleus accumbens of autoimmune MRL-lpr mice. Behav Brain Res (2006) 166:32-8. doi:10.1016/j.bbr.2005.07.030
121. Sakic B, Lacosta S, Denburg JA, Szechtman H. Altered neurotransmission in brains of autoimmune mice: pharmacological and neurochemical evidence. J Neuroimmunol (2002) 129:84-96. doi:10.1016/S0165-5728(02)00171-6
122. Ballok DA, Earls AM, Krasnik C, Hoffman SA, Sakic B. Autoimmune-induced damage of the midbrain dopaminergic system in lupus-prone mice. J Neuroimmunol (2004) 152:83-97. doi:10.1016/j.jneuroim.2004.04.003
123. Jafari M, Ahangari G, Saberi M, Samangoui S, Torabi R, Zouali M. Distorted expression of dopamine receptor genes in systemic lupus erythematosus. Immunobiology (2013) 218:979-83. doi:10.1016/j.imbio.2012.11.002
124. Kuo CT, Veselits ML, Leiden JM. LKLF: a transcriptional regulator of single-positive T cell quiescence and survival. Science (1997) 277:1986-90. doi:10.1126/science.277.5334.1986
125. Walker SE. Bromocriptine treatment of systemic lupus erythematosus. Lupus (2001) 10:762-8. doi:10.1191/096120301666625458
126. Peeva E, Grimaldi C, Spatz L, Diamond B. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest (2000) 106:1373-9. doi:10.1172/JCI10420